Compare RES & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | COLL |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1995 | 2015 |
| Metric | RES | COLL |
|---|---|---|
| Price | $6.30 | $36.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $5.44 | ★ $50.83 |
| AVG Volume (30 Days) | ★ 2.2M | 387.1K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.15 | ★ 1.73 |
| Revenue | ★ $41,919,000,000.00 | $780,567,000.00 |
| Revenue This Year | $5.01 | $6.07 |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | $40.93 | ★ $21.55 |
| Revenue Growth | ★ 2216.21 | 23.62 |
| 52 Week Low | $4.10 | $23.23 |
| 52 Week High | $6.85 | $50.79 |
| Indicator | RES | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 20.35 |
| Support Level | $4.35 | $34.30 |
| Resistance Level | $6.85 | $39.85 |
| Average True Range (ATR) | 0.23 | 1.57 |
| MACD | 0.04 | -0.84 |
| Stochastic Oscillator | 95.83 | 4.48 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.